Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04005989
Other study ID # ADMIRE
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date December 1, 2021
Est. completion date December 20, 2022

Study information

Verified date July 2021
Source Hospital do Coracao
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Treatment of ischemic myocardium has been the subject of intense research in recent years and stem cell therapy is one of the great promises. The InCor laboratory has studied cells from different backgrounds as candidates for cell therapy in the context of myocardial infarction. Evidence in preclinical studies of the application of stromal (mesenchymal) adipose tissue (hASC) in the ischemic heart by both the InCor group (in the animal model in rodents and pigs) and others in the literature suggest relevant benefits on the decrease of deterioration post-infarction. More recently it has been demonstrated that it arises mainly from the formation of new vessels due to paracrine factors, which are secreted by the injected cells. There are currently no studies in Brazil in which the safety of injecting different doses of hASC cells into the heart has been particularly evaluated. Recently, two studies have demonstrated the clinical applicability of hASC in patients with peripheral ischemic disease and stroke. Thus, the objective of this work will be to test the hypothesis that the implantation of autologous stromal cells derived from adipose tissue combined with myocardial revascularization surgery in patients with coronary artery disease


Description:

To test the hypothesis that the implantation of adipose-derived autologous cells derived from adipose tissue (hASCs) combined with coronary artery bypass grafting in patients with coronary artery disease is safe and well tolerated, besides being able to promote regional perfusion increase in the injected segments.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 20, 2022
Est. primary completion date November 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - signing the Informed Consent Form (TCLE) - the patient must be a patient with obstructive atherosclerotic coronary artery disease - sex: both men and women are eligible- - Age: between 18 and 80 years of age - the patient should present clinical evidence (angina pectoris or angina equivalent) OR imaging (stress echocardiography, myocardial perfusion scintigraphy, cardiac magnetic resonance imaging) of myocardial ischemia, invasively stratified with coronary angiography - the presence of myocardial ischemia should be confirmed by at least 2 (two) distinct diagnostic methods performed within one year of the patient's inclusion in the study - the patient is a candidate for myocardial revascularization surgery but coronary obstructive lesions, in their entirety, are NOT amenable for surgical treatment in the opinion of the surgeon (main surgeon), depending on the anatomical type, extent or distal involvement of the lesions OR, even if they can be treated surgically as a whole, an unsatisfactory surgical outcome is anticipated in terms of functional gain (restoration of myocardial perfusion) Exclusion Criteria: do not meet ALL criteria for inclusion - have a concomitant severe disease, at an advanced stage, or with an unquestionable shortening of life expectancy (<1 year), or that prevents complementary examinations and / or attendance at follow-up visits - have a confirmed diagnosis, previous history and / or past treatment of neoplasia, of any location and staging, in the last 5 years - being in clinical treatment or awaiting surgical treatment of neoplasia, any location and staging - present, during the outpatient investigation, unequivocal findings of neoplasia - have symptoms attributable exclusively to left ventricular dysfunction, although of ischemic etiology, without the evidence of current myocardial ischemia, by at least two (2) methods of evaluation - presented severe left ventricular dysfunction as defined by transthoracic echocardiography due to the finding of a left ventricular ejection fraction <0.25 (Simpson's method) - have a history or current diagnosis of severe ventricular arrhythmias such as sustained ventricular tachycardia unless an automatic cardioverter-defibrillator has been implanted previously - Concurrent heart diseases of other etiologies (valvular, idiopathic, hypertensive, Chagasic, etc.). - have a history of acute coronary syndrome (unstable angina or acute myocardial infarction) in the last 3 months - present chronic renal failure in dialysis treatment - have participated in other cell therapy studies in the past 2 years - Pregnant women - patients diagnosed with acquired immunodeficiency syndrome (AIDS)

Study Design


Intervention

Biological:
Stromal Cells Injection
Adipose stromal cell

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hospital do Coracao

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiovascular Death Death due to stroke, myocardial infarction or other cardiovascular causes 12 months
Primary Unstable angina Occurence of angina requiring hospitalization 12 months
Primary Acute myocardial infarction Occurence of acute myocardial infarction (with or without ST segment elevation) 12 months after procedure
Primary Unplanned myocardial revascularization surgery Need for urgent surgical myocardial revascularization 12 months
Primary Unplanned myocardial revascularization through angioplasty Need for urgent non-surgical myocardial revascularization 12 months
Secondary All cause mortality 12 months
Secondary Stroke 12 months
Secondary Cardiogenic shock 12 months
Secondary Occurence of complex ventricular arrhythmia 12 months
Secondary New onset atrial fibrilation 12 months
Secondary Occurence of acute pulmonary edema 12 months
Secondary Pulmonary embolism 12 months
Secondary Acute respiratory failure of any cause 12 months
Secondary Septic shock Disseminated infection requiring vasopressors 12 months
Secondary New onset cancer Diagnosis of any cancer at any stage during study period 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A